Date: 2015-10-14
Type of information: Series A financing round
Company: Minoryx Therapeutics (Spain)
Investors: Ysios Capital (Spain) Kurma Partners (France) Roche Venture Fund (Switzerland) Idinvest Partners (France) Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain)
Amount: €19.4 million ($21.7 million)
Funding type: series A financing round
Planned used: The funds raised will be used to complete Mynoryx Therapeutics\' team, especially in R&D, to move lead project MIN-102 to clinical validation and to further develop a pipeline of non-competitive pharmacological chaperones identified through the company’s innovative proprietary platform, SEE-Tx. MIN-102, Minoryx’s candidate for X-linked adrenoleukodystrophy (X-ALD), is in the preclinical stage. It is a differentiated PPAR gamma agonist with a superior profile for CNS related diseases with excellent in-vivo efficacy, a comprehensive development plan and early involvement from key opinion leaders. PPAR gamma agonists have shown strong potential in animal models related to the various phenotypes associated with X-ALD. Minoryx’s candidate is the only product in development for potential use across all the main phenotypes. PPAR gamma agonists also showed efficacy in multiple models of neurodegenerative diseases, meaning that MIN-102 also offers a significant potential for indication expansion.
Others: * On October 14, 2015, Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, announced it has completed a Series A funding round of €19.4M ($21.7M). Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners and Chiesi Ventures. Existing investors Caixa Capital Risc, the venture capital division of ‘la Caixa’ and HealthEquity also participated in the round. With this fundraising, the company also welcomes three new board members: Laia Crespo from Ysios Capital, Thierry Laugel from Kurma Partners and Monique Schiersing from Roche Venture Fund.
Therapeutic area: Rare diseases
